TCR2 Therapeutics TCRR

$ 1.48 0.0%

Quarterly report 2023-Q1
added 05-11-2023

TCR2 Therapeutics Balance Sheet 2011-2024 | TCRR

Annual Balance Sheet TCR2 Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-7.6 M	-196 M	-94.2 M	-65.3 M	-47.7 M	-19.8 M	-7.99 M	-	-	-	-	-
Long Term Debt	3.32 M	23 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	21.8 M	3.37 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	807 K	546 K	210 M	47.1 M	29.2 M	-	-	-	-	-
Total Current Liabilities	64.1 M	18.6 M	8.84 M	7.53 M	-	-	-	-	-	-	-	-
Total Liabilities	67.4 M	41.9 M	9.65 M	8.08 M	215 M	48.4 M	30.1 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-501 M	-350 M	-250 M	-183 M	-85.6 M	-26.3 M	-11.9 M	-	-	-	-	-
Total Assets	208 M	323 M	246 M	169 M	129 M	22 M	18.3 M	-	-	-	-	-
Cash and Cash Equivalents	32.7 M	223 M	94.2 M	65.3 M	48 M	-	-	-	-	-	-	-
Book Value	141 M	281 M	237 M	160 M	-85.7 M	-26.3 M	-11.9 M	-	-	-	-	-
Total Shareholders Equity	141 M	281 M	237 M	160 M	-85.7 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet TCR2 Therapeutics

	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	2.71 M	3.32 M	37.7 M	43.2 M	36.8 M	23 M	23.6 M	24 M	35 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	50.2 M	67.4 M	74.4 M	81.8 M	67.9 M	41.9 M	40.5 M	39.2 M	46.4 M	9.65 M	9.65 M	9.65 M	9.65 M	8.08 M	8.08 M	8.08 M	8.08 M	5.9 M	5.9 M	5.9 M	5.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-542 M	-501 M	-441 M	-410 M	-379 M	-350 M	-322 M	-296 M	-271 M	-250 M	-250 M	-250 M	-250 M	-183 M	-183 M	-183 M	-183 M	-85.6 M	-85.6 M	-85.6 M	-85.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	152 M	208 M	273 M	308 M	323 M	323 M	347 M	368 M	396 M	246 M	246 M	246 M	246 M	169 M	169 M	169 M	169 M	129 M	129 M	129 M	129 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	14.4 M	32.7 M	54 M	44.2 M	74.1 M	223 M	262 M	249 M	218 M	94.7 M	94.2 M	94.2 M	94.2 M	65.3 M	65.3 M	65.3 M	65.3 M	47.7 M	47.7 M	47.7 M	47.7 M	20.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	101 M	141 M	199 M	226 M	255 M	281 M	306 M	329 M	350 M	237 M	237 M	237 M	237 M	160 M	160 M	160 M	160 M	124 M	124 M	124 M	124 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	101 M	141 M	199 M	226 M	255 M	281 M	306 M	329 M	350 M	237 M	237 M	237 M	237 M	160 M	160 M	160 M	160 M	-85.7 M	-85.7 M	-85.7 M	-85.7 M	-26.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency